Researchers found a positive correlation between glioblastoma cell proliferation and lactate metabolic indicators. Based on this observation, the researchers developed a biomimetic formulation using targeted delivery agents for lactate metabolism-based synergistic therapy against glioblastoma brain cancer.
Researchers say the gut microbiome may be a viable targetable biomarker to improve immunotherapy responses in those with glioblastoma and a range of other cancers.
Researchers have developed drug-carrying nanoparticles that cross the blood-brain barrier, allowing for more effective delivery to the brain than conventional medications. The nanoparticles can get into tumors and kill glioblastoma brain cancer cells.
Study reveals the ZNF117 gene is a major regulator of glioblastoma tumor cells.
INSR, a protein essential for insulin activity, plays a critical role in stem cell longevity. Additionally, inactivating INSR in glioblastoma brain cancer stem cells inhibits the growth of primitive tumor forming cells.
Variations in the TSPO neuroinflammation-associated protein's structure correlates with worse survival outcomes for male glioblastoma brain cancer patients than females.
A combination of approved and novel therapeutics improved survival rates and reduced both tumor volume and growth for those suffering from glioblastoma brain cancer.
Cellular reprogramming of glioma cells into neural cells may be a promising treatment for glioblastoma brain cancer.